It is now well established that castration-resistant disease can be effectively treated using newer androgen receptor-targeting agents such as abiraterone and enzalutamide.
Celestia S. Higano, MD
Advertisement
Articles by Celestia S. Higano, MD
Advertisement
Latest Updated Articles
- Targeting the Androgen Receptor Signaling Axis to Reduce Testosterone Levels in Prostate Cancer: How Low Should We Go?
Published: August 15th 2014 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
ESMO 2025: Key Anticipated Updates in Breast and Lung Tumors
2
Ficerafusp Alfa/Pembrolizumab Receives FDA BTD in Front-Line HNSCC
3
Tucatinib Regimen Improves PFS in HER2+ Metastatic Breast Cancer
4
Safety Strategies for GPRC5D-Directed and T-Cell Engager Therapies
5
